Susan Li

2.5k total citations · 2 hit papers
45 papers, 1.7k citations indexed

About

Susan Li is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Electrical and Electronic Engineering. According to data from OpenAlex, Susan Li has authored 45 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 14 papers in Radiology, Nuclear Medicine and Imaging and 14 papers in Electrical and Electronic Engineering. Recurrent topics in Susan Li's work include Prostate Cancer Treatment and Research (21 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and Integrated Circuits and Semiconductor Failure Analysis (12 papers). Susan Li is often cited by papers focused on Prostate Cancer Treatment and Research (21 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and Integrated Circuits and Semiconductor Failure Analysis (12 papers). Susan Li collaborates with scholars based in United States, Canada and France. Susan Li's co-authors include B. Yа. Alekseev, Karim Fizazi, Suneel Mundle, Kim N., Giri Sulur, Luis Fein, Andrew Protheroe, Mustafa Özgüroğlu, Susan Feyerabend and Nobuaki Matsubara and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and The Journal of Urology.

In The Last Decade

Susan Li

40 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

2019 517 citations Karim Fizazi, Luis Fein et al. The Lancet Oncology profile →
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

2012 336 citations Kenneth J. Pienta, Jean-Pascal Machiels et al. Investigational New Drugs profile →

Peers

Countries citing papers authored by Susan Li

Since Specialization

Citations

This map shows the geographic impact of Susan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Li more than expected).

Fields of papers citing papers by Susan Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Li. The network helps show where Susan Li may publish in the future.

Co-authorship network of co-authors of Susan Li

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Li. A scholar is included among the top collaborators of Susan Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Li. Susan Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Detecting Wafer-Level Cu Pillar Defects using Advanced 3D X-ray Microscopy (XRM) with Submicron Resolution 2024 ·Journal of Failure Analysis and Prevention ·Susan Li, J.W. Frame, (unknown), (unknown), Ming Zhang, (unknown), Allen Gu, (unknown)	0
2	Nano-probing Technique for Flip-Flop Circuit with Diffusion Defect 2024 ·(unknown), (unknown), Susan Li	0
3	An Improved Backside Deprocessing Technique for Advanced IC Devices 2024 ·Proceedings - International Symposium for Testing and Failure Analysis ·Susan Li, (unknown), Zhaofeng Wang, (unknown), Ming Zhang, (unknown), (unknown)	1
4	Detecting Wafer Level Cu Pillar Defects Using Advanced 3D X-ray Microscopy (XRM) with Submicron Resolution 2023 ·Proceedings - International Symposium for Testing and Failure Analysis ·Susan Li, J.W. Frame, (unknown), (unknown), Ming Zhang, (unknown), Allen Gu, (unknown)	1
5	Novel Nano-probing Technique for Column Short Failure in Flash Memory Devices 2023 ·(unknown), (unknown), Susan Li	1
6	An extended cross-efficiency evaluation method based on information entropy with an application to the urban logistics industry 2022 ·Journal of Modelling in Management ·(unknown), (unknown), Susan Li	3
7	Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy 2021 ·European Urology Focus ·Stéphane Oudard, Boris Hadaschik, Fred Saad, David Cella, Ethan Basch, Julie N. Graff, Hiroji Uemura, Shiva Dibaj, Susan Li, Sabine Brookman‐May, Peter De Porre, Katherine B. Bevans, Jeremiah Trudeau, Eric J. Small, Matthew R. Smith	14
8	Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study 2021 ·The Lancet Oncology ·Fred Saad, Eleni Efstathiou, Gerhardt Attard, Thomas W. Flaig, Fábio Franke, Oscar B. Goodman, Stéphane Oudard, Thomas Steuber, Hiroyoshi Suzuki, Daphne Wu, (unknown), Peter De Porre, Sabine Brookman‐May, Susan Li, Jinhui Li, Shibu Thomas, Katherine B. Bevans, Suneel Mundle, Sharon McCarthy, Dana E. Rathkopf	64
9	Apalutamide and Overall Survival in Prostate Cancer 2020 ·European Urology ·Matthew R. Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Hiroji Uemura, Peter De Porre, Alexis K. Smith, Sabine Brookman‐May, Susan Li, Ke Zhang, Brendan Rooney, Angela Lopez‐Gitlitz, Eric J. Small	181
10	Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study 2019 ·European Urology ·Nobuaki Matsubara, Kim N., Mustafa Özgüroğlu, A. Rodrı́guez-Antolı́n, Susan Feyerabend, Luis Fein, B. Yа. Alekseev, Giri Sulur, Andrew Protheroe, Susan Li, Suneel Mundle, Peter De Porre, NamPhuong Tran, Karim Fizazi	78
11	Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial breakdown → 2019 ·The Lancet Oncology ·Karim Fizazi, (unknown), Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Giri Sulur, Yesenia Luna, Susan Li, Suneel Mundle, Kim N.	517
12	Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). 2019 ·Journal of Clinical Oncology ·Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Giri Sulur, Yesenia Luna, Susan Li, Suneel Mundle, Kim N.	8
13	Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial 2018 ·The Lancet Oncology ·Fred Saad, David Cella, Ethan Basch, Boris Hadaschik, Paul N. Mainwaring, Stéphane Oudard, Julie N. Graff, Kelly McQuarrie, Susan Li, Stacie Hudgens, (unknown), Angela Lopez‐Gitlitz, Margaret K. Yu, Matthew R. Smith, Eric J. Small	88
14	Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. 2018 ·Journal of Clinical Oncology ·Karim Fizazi, Susan Feyerabend, Nobuaki Matsubara, Mustafa Özgüroğlu, Luis Fein, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Giri Sulur, Andrew Protheroe, Peter De Porre, Susan Li, Youn C. Park, Suneel Mundle, NamPhuong Tran, Kim N.	4
15	Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate 2016 ·The Journal of Community and Supportive Oncology ·David Cella, Susan Li, Tracy Li, Thian Kheoh, Mary B. Todd, Ethan Basch	8
16	Complementary and Alternative Medicine Use and Benefit Finding Among Cancer Patients 2013 ·The Journal of Alternative and Complementary Medicine ·Sheila N. Garland, (unknown), Krupali Desai, Susan Li, Corey J. Langer, Tracey L. Evans, Jun J. Mao	57
17	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial 2013 ·The Lancet Oncology ·Ethan Basch, Karen A. Autio, Charles J. Ryan, Peter Mulders, Neal D. Shore, Thian Kheoh, Karim Fizazi, Christopher J. Logothetis, Dana E. Rathkopf, Matthew R. Smith, Paul N. Mainwaring, Yanni Hao, Thomas W. Griffin, Susan Li, Michael L. Meyers, Arturo Molina, Charles S. Cleeland	114
18	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer breakdown → 2012 ·Investigational New Drugs ·Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers, B. Yа. Alekseev, М. I. Shkolnik, Simon J. Crabb, Susan Li, Shobha Seetharam, Thomas A. Puchalski, Chris H. Takimoto, Yusri Elsayed, Fitzroy W. Dawkins, Johann S. de Bono	336
19	Identification of a novel interaction between the Ca²⁺-binding protein S100A11 and the Ca²⁺- and phospholipid-binding protein annexin A6 2006 ·American Journal of Physiology-Cell Physiology ·Ning Chang, Cindy Sutherland, (unknown), Robert J. Winkfein, William B. Wiehler, Mark Pho, (unknown), Susan Li, David P. Wilson, Enikö Kiss, Michael P. Walsh	31
20	Estrogen receptor ligands. Part 4: The SAR of the syn-dihydrobenzoxathiin SERAMs 2004 ·Bioorganic & Medicinal Chemistry Letters ·Seongkon Kim, Jane Y. Wu, Helen Y. Chen, Elizabeth T. Birzin, Wanda Chan, Yi Yang, Lawrence F. Colwell, Susan Li, Johanna Dahllund, Frank DiNinno, Susan P. Rohrer, James M. Schaeffer, Milton L. Hammond	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact